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Abstract 
Background & aims: There is a paucity of unbiased data on the natural history of hepatitis C 
virus (HCV) infection in injecting drug users (IDUs). The purpose of this study was to assess 
the risk of developing advanced fibrosis associated with chronic hepatitis C (CHC) infection 
among injecting drug users (IDUs) who underwent an autopsy. 
Methods: A longitudinal cohort design was applied, in which the stage of liver fibrosis in anti-
HCV positive IDUs with or without chronic HCV infection was assessed in liver tissue from 
autopsies performed up to 35 years after HCV exposure. The cohort originated from 864 
IDUs consecutively admitted for drug abuse treatment 1970-1984. Stored sera, mostly drawn 
at the time of admission for drug treatment, were available in 635 subjects. 220 out of 523 
anti-HCV positive subjects had died before 2009. Liver tissue from autopsies was available 
from 102/220 subjects, of which 61 were HCV RNA positive. Liver sections were classified 
according to METAVIR scores for fibrosis. Two pathologists, both blinded for serologic 
results, scored sections of liver tissue.  
Results: Among HCV RNA positive subjects 16.4% (10/61) had septal fibrosis (F3) or 
cirrhosis (F4) compared to 2.4% (1/41) among anti HCV positive/HCV RNA negative 
subjects (p=0.026). Of 18 HCV RNA positive subjects autopsied <15 years after HCV 
exposure none had F3 or F4. Among subjects autopsied > 25 years after exposure 35% (6/17) 
had F3-F4. 
Conclusions: Among IDUs chronically infected by HCV, 1/3 developed septal fibrosis or 
cirrhosis 25 years or more after exposure.  
Keywords: Hepatitis C; HCV; Liver fibrosis; Cirrhosis; METAVIR; Steatosis; Longitudinal, 
Drug abuse; IDU; PWID. 
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Abbreviations:  HCV, hepatitis C virus; IDU, injecting drug user; RNA, ribonucleic acid; 
anti-HCV; hepatitis C antibody; CHC, chronic hepatitis C; HBsAg, hepatitis B surface 
antigen; anti-HBc, hepatitis B core antibody; HCC, hepatocellular carcinoma; CI, confidence 
interval; IQR, interquartile range; ALT, alanine transaminase 
 
Introduction 
Hepatitis C virus (HCV) infection has been endemic among injecting drug users (IDUs) in 
Norway for four decades [1]. The risk of serious illness from liver disease increases with 
age [2]. There are few longitudinal studies on HCV-induced liver fibrosis with established 
time-point of HCV exposure, and the great majority have been performed among patients 
infected through medical procedures such as transfusions and medical injections with 
infected syringes or sera containing HCV [3-7].  In Western countries the main cause of 
HCV-infection has been the use of contaminated syringes and needles among IDUs. Still, to 
the best of our knowledge few longitudinal long-term studies have been published with 
IDUs as the main subjects, and most have used a limited observation time [8-10]. There is a 
number of crossectional studies of HCV related fibrosis [11]. However, these studies are 
intrinsically hampered by serious biases.  
IDUs are different in several aspects from other groups of patients chronically infected by 
HCV. They have an increased burden of disease, are usually young at the time of exposure, 
and in most cohorts about 2/3 are males. Some studies also indicate increased use of alcohol 
among IDUs [12, 13]. There is a need for unbiased long-term studies which follow IDUs 
with all degrees of chronic HCV-infections for several decades.  
The aim of the present study was to assess the risk of developing advanced fibrosis in IDUs 
with chronic HCV infection. 
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Patients and methods 
Study design 
The study had a longitudinal cohort design. It was based on a cohort of IDUs admitted to 
Statens klinikk for narkomane (National Clinic for Drug Abuse) during the years 1970 – 
1984[14].  
Participants 
Consecutive subjects admitted for drug abuse treatment at Statens klinikk for narkomane 
1970-1984 were included if they had sera drawn at the time of admission or later with 
detectable anti-HCV and with autopsy material available.  
Among the 864 patients admitted, 523 were anti-HCV positive and could be tested for HCV 
RNA. By December 31, 2008, 220 of the 523 had died, and liver sections from autopsies were 
available for 102, the study group. These were divided into two groups, the anti-HCV 
positive/HCV RNA positive who had chronic hepatitis C (CHC) and the anti-HCV 
positive/HCV RNA negative subjects who had been exposed to HCV with later spontaneous 
clearance. The 118 who died and were anti-HCV positive, without liver tissue available for 
analysis, constituted a comparison group for analysis of representativity. Details on the 
selection of subjects are shown in Fig.1.  
The patients were followed up through register linkage to the Causes of Death Registry 
(Statistics Norway), which includes information on whether an autopsy had been performed. 
Data on HCV antiviral medical treatment prior to 2004 were obtained by linkage to 
Scandinavian research trials on antiviral HCV treatment and from 2004 through the 
Norwegian Prescription Database (Norwegian Institute of Public Health), which began 
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operation that year and included all treated cases in Norway from 2004 onward. Norwegian 
11-digit identification numbers were used for register linkage. The cohort was also linked to 
The Norwegian Cancer Registry for information on hepatocellular carcinoma (HCC) and to 
the Nordic Liver Transplant Registry. 
Serum examination and time point of HCV transmission 
As acute HCV infection was not registered in any of the patients, the time point of HCV 
transmission had to be estimated. All patient case records at Statens klinikk for narkomane 
were studied by one of the authors (KBK) to establish age at first drug injection. Medical 
records for most patients contained this information directly, and for most of the others it was 
possible to establish the age of first injection with reasonable certainty through circumstantial 
information, This included information about heroin or morphine misuse, or finding of anti-
HBs antibodies, both of which in this population with high degree of certainty would imply 
drug injections. The time point of HCV transmission in most cases was estimated as two years 
after the first injection of drugs. Details on these procedures have been described elsewhere 
[14]. 
At the time of admission for treatment of drug abuse or later, serum from most of the patients 
was drawn for analysis and stored at the Norwegian Institute of Public Health  (NIPH) at -20° 
C[14]. The sera were examined for anti-HCV (Ortho-Clinical Diagnostics HCV 3.0 ELISA), 
hepatitis B surface antigen (HBsAg), and hepatitis B core antibody (anti-HBc) (Bio-Rad 
Monolisa HBsAg Ultra and anti-HBc PLUS). HCV RNA was detected by an “in house” 
polymerase chain reaction (PCR) to detect viral RNA (detection limit 500 virus copies per ml 
corresponding to 100 IU per ml) [15].  
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Evaluation of liver tissue 
When autopsy is performed in Norway, liver tissue is regularly stored. Eighty-one of the 
included samples of liver tissue were from autopsies performed at the Institute of Forensic 
Medicine at the University of Oslo, which is now part of the Norwegian Institute of Public 
Health. The remaining 21 originated from autopsies performed at other departments of 
pathology or forensic pathology. Liver tissue was available from all 102 autopsies as tissue 
blocks fixated in standard 10% neutral formalin and paraffin.  
New histological sections were processed at the Department of Forensic Pathology and 
Clinical Forensic Medicine at the Norwegian Institute of Public Health. Three histological 
sections from each sample were cut to a 4 μm thickness and stained with hematoxylin eosin 
(HE), acid fuchsin orange G-stain (AFOG) and Perls’ iron stain. The area of sections varied 
between 0.5 cm
2
 and 3.0 cm
2.
   
All three sections from each case were examined by two pathologists working independently 
and blinded for serologic results and anamnestic information. The liver pathology was scored 
according to the METAVIR scales for fibrosis stage (F0 - F4) where F0 = no fibrosis, F1 = 
portal fibrosis without septa, F2 = portal fibrosis with few septa, F3 = septal (or bridging) 
fibrosis and F4 = cirrhosis [16]. Inflammatory activity, steatosis and autolysis were also 
graded on four point scales from 0 to 3.  
Statistics 
Rates of advanced fibrosis (F3-F4) were calculated as cases of F3-F4/total cases. In the 
Kaplan- Meier plot, the end point was death accompanied with advanced fibrosis (F3-F4). 
Subjects dying without advanced fibrosis were censored. Log rank tests were used for testing 
significance in Kaplan-Meier analysis. The rate of progression of fibrosis was calculated as 
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METAVIR stage/years since HCV-exposure. Pearson’s Chi-squared test was used for 
comparison of frequencies of ordinal variables. Significance level was set at 5% and 
confidence interval (CI) at 95%. The Statistical Package for the Social Sciences (SPSS) 
version 18.0 was employed for statistical analysis. 
Ethics 
The study was approved by the National Committee for Research Ethics. No consent was 
collected from the participants at the time of admission to treatment, and in accordance with 
the National Committee for Research Ethics no later attempt was made to collect consent 
from relatives. The Director of Public Prosecutions approved the use of tissue material 
collected at medicolegal autopsies. 
Results 
Patient description 
The study group consisted of 102 anti-HCV positive individuals. Of this group 76 (74.5%) 
were males, 61 (59.8%) were HCV RNA positive. Among males 43/76 (56.6%) and among 
females 18/26 (69.2%) were HCV RNA positive. The mean time from the first drug injection 
to admittance for drug abuse treatment was 5.4 years (SD 3.0) and from HCV exposure to 
admittance 2.7 years (SD 3.6). The mean age at autopsy was 37.3 years (SD 9.4), and mean 
observation time from HCV exposure to autopsy was 16.9 years (SD 9.3).  
Causes of death 
The main cause of mortality was drug-related deaths (mainly opioid poisoning). A total of 
five individuals had committed suicide, while seven died from other external causes (Table 1). 
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Death by liver disease occurred in 3/61 (4.9%) of HCV RNA positive patients versus none of 
the 41 HCV RNA negative patients. One of the liver deaths was due to HCC. No other case of 
HCC was registered, nor any liver transplantation. 
Fibrosis score and rate of fibrosis progression 
We observed cirrhosis (F4) in 8/102, (8%, CI 3% – 13%) of autopsied anti-HCV positive 
IDUs. In the group with CHC 7/61, (11%, CI 3% – 19%) had cirrhosis compared to 1/41, 
(2%, CI 0% - 7%) among the HCV RNA negative subjects.  
The proportion of advanced fibrosis (F3-F4) was 10/61 (16%, CI 7% - 26%) among patients 
with CHC, and 1/41 (2%, CI 0% - 7%) among HCV RNA negative subjects (p=0.026). 
The proportion of advanced fibrosis increased according to the time since HCV exposure 
(Table 2). Among 26 subjects with CHC autopsied up to 15 years after HCV exposure, none 
had F3-F4. Among the individuals who died 15 - 25 years after exposure, 4/18 (22%, CI 3% - 
41%) had F3-F4, and after more than 25 years since exposure 6/17 (35%, CI 13% - 58%) had 
F3-F4.  On the other hand, 16/26 (62%, CI 43% - 80%) of subjects with CHC autopsied more 
than 20 years after exposure had no fibrosis (F0)  or only portal fibrosis (F1) (Table 2). 
Median time from HCV exposure to autopsy for subjects with F0-F2 was 14.8 years 
(interquartile range (IQR) 8.5 – 22.5) and for F3-F4 26.8 years (IQR 23.1 – 28.9).  
Development of advanced fibrosis (F3-F4) is illustrated by the Kaplan-Meier plot in Fig. 2. 
End point in the figure is the combination of death and advanced fibrosis (F3-F4), while those 
with stage F0-F2 were censored. The first two cases of advanced fibrosis occurred 17 and 19 
years after HCV exposure, respectively. The number of patients at risk 30 years after HCV 
exposure was too small for reliable results. Fig. 3 demonstrates the stage of fibrosis in 
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different age groups among the HCV RNA negative and positive individuals respectively, and 
implies that 6/16 (38%, CI 14% - 62% ) of HCV RNA positive subjects autopsied at age >45 
years had advanced fibrosis . 
Among the 41 HCV RNA negative subjects, one male had developed cirrhosis 33 years after 
HCV-exposure. This individual was both anti-HBc positive and anti-HCV positive but with 
no sign of chronic viral hepatitis. He died from opioid intoxication at age 50. There was no 
information regarding liver disease or use of alcohol in his death certificate. 
The median rate of fibrosis progression (METAVIR units/year) for HCV RNA positive 
patients was 0.068 (IQR 0.038 – 0.128, range 0.0 – 0.63), mean 0.097 (SD 0.094). 
Five subjects were HBsAg positive, two of whom had HBV/HCV coinfection. One patient 
with HBV/HCV coinfection autopsied 29 years after HCV exposure had F2. The other four 
HBsAg positive individuals autopsied 6-30 years after HCV exposure had F0 or F1. 
Only one subject had received antiviral HCV-treatment. She died 27 years after HCV 
exposure from opioid poisoning, a few months after treatment. Her fibrosis score was F1.  
One subject with CHC had HIV as cause of death. At autopsy she had F1 14 years after the 
HCV exposure. 
Inflammatory activity and steatosis 
There were non-significant associations between HCV RNA and both inflammatory activity 
and steatosis (Table 3a). However, the associations between inflammatory activity and 
fibrosis and between steatosis and fibrosis were clearly significant (Table 3b). 
Study group compared to group of dead IDUs without liver tissue available for analysis 
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(comparison group) 
The study group of 102 subjects with available liver tissue was compared with the 118 who 
died in the same period without liver tissue available for assessment of fibrosis (Fig. 1). 
The study group and the comparison group did not differ concerning gender (males 74.5% 
and 72.0% respectively), mean age at HCV exposure (20.9 years and 19.8 years) or chronic 
HCV infection (HCV RNA positive 59.8% and 61.9%). However, the groups differed 
significantly regarding causes of death, with drug related deaths (mostly opioid poisoning) 
dominant in the autopsied study group and other causes more frequent in the comparison 
group (Table 4). 
Quality of liver specimens and the evaluation of fibrosis 
All sections had at least some signs of autolysis (grade 1). Of the 102 liver tissue specimens 
suitable for the assessment of fibrosis, seven were unsuitable for the evaluation of 
inflammatory activity and eight of steatosis assessment due to autolysis. 
The scoring of fibrosis differed by one stage among the two pathologists in 33 cases, of which 
23 were HCV RNA positive. Most discrepancies were between F1 and F2, but in three cases 
there were discrepancies between F2 and F3. In cases that differed with one stage, the lower 
score was selected. In four cases the scoring differed by two stages. These cases were 
reassessed by each pathologist separately, resulting in four scores for each case. The most 
frequent score was chosen.  
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Discussion 
In this study of autopsied IDUs, chronic HCV infection was clearly associated with the 
development of advanced fibrosis, as 16% of those who were HCV RNA positive had 
advanced fibrosis compared to 2% of those who were HCV RNA negative, after a mean time 
of 16 years since HCV exposure. 
About 1/3 of the subjects with a chronic infection, observed for more than 25 years, had 
developed septal fibrosis or cirrhosis. Thus, among drug users in Norway older than 45 years, 
one in three with chronic HCV infection may be expected to have, or be in the process of 
developing, cirrhosis. On the other hand it is also noticeable that 62% of subjects with CHC 
autopsied more than 20 years after exposure had no or minimal fibrosis 
The median fibrosis progression rate of 0.07 per year observed in this cohort was similar to or 
lower than reported in other studies of patients with chronic HCV-infection [16-20], but the 
progression rate was higher than in studies of young females who contracted an HCV-
infection accidentally as a result of infected anti-D immunoglobulin in Ireland and Germany 
[5, 21]. In a meta-analysis of the stage-specific fibrosis progression rate in different 
populations of HCV-patients, the mean progression rate among the IDUs were: F0-F1 0.116, 
F1-F2 0.085, F2-F3 0.085 and F3-F4 0.130 [20]. This corresponds well to the overall mean 
progression rate of 0.097 in our study. 
Cirrhosis was observed in 8% of this cohort of 102 autopsied IDUs. This is in line with an 
Australian autopsy study where 11% of anti-HCV positive autopsy cases of drug-related 
deaths had cirrhosis [22]. In a similar Danish autopsy study of fatal opioid overdose cases 
cirrhosis was observed among 19% (6/32) of anti-HCV positive subjects after more than 20 
years of drug use [23], compared to 13% (6/46) in our study (Table 2).   
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Among anti-HCV positive/HCV RNA positive individuals, 11% had cirrhosis compared to 
2% of the anti-HCV positive/HCV RNA negative ones. We are not aware of other autopsy 
studies that stratified the prevalence of cirrhosis according to HCV RNA status. 
A study of HCV-related mortality, based on the same Norwegian population of IDUs as this 
study, demonstrated increased liver-related mortality 25-30 years after HCV transmission 
[14]. This is in accordance with the results in the present study. 
The lack of significant associations between HCV RNA and steatosis/inflammatory activity in 
this study might be due to Type 2 errors, as these associations are well-documented in the 
literature [2, 24]. The clear associations between inflammatory activity and fibrosis and 
between steatosis and fibrosis also are in line with previous studies. 
The important strengths of this study were the unbiased recruitment to the study, the relevant 
comparison with anti-HCV positive/HCV RNA negative subjects, long observation time, and 
secure identification through the Norwegian 11 digit personal code which ensures correct 
identity. Patients were included in this cohort when they entered treatment for drug abuse, 
typically five years after having started intravenous drug abuse and even a shorter time after 
being exposed to HCV. Thus, the sample represents the full spectrum of HCV related fibrosis 
progression without the bias in a more serious direction seen in cross-sectional studies which 
tends to include patients with signs of liver disease as raised alanine transaminase (ALT) 
activity. The HCV RNA negative patients were anti-HCV positive and had the same 
experience regarding drug abuse, were of the same age and were admitted for drug abuse 
treatment at the same clinic during the same period. This may compensate for the lack of 
knowledge about factors known to influence development of HCV-related fibrosis, such as 
use of alcohol, insulin resistance and body mass index [18].  
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Another strength was the fact that the histological evaluations were based on full sections of 
liver, not on needle biopsies like in most other studies. Thus sampling bias which could 
interfere with the evaluation was avoided [25-27].  
This is, to the best of our knowledge, the first time such information from autopsies has been 
used in a longitudinal study of fibrosis in IDUs infected by HCV. The importance of this is 
underlined by a recent study based on digitally simulated biopsies from liver tissue which 
demonstrated great variability in the scoring of fibrosis stage in biopsies as compared to the 
real “gold standard” when the examination of liver tissue is performed on liver tissue obtained 
by resection or transplantation [28].  
A limitation of the present study was the relatively small sample size. This inhibits definite 
conclusions concerning rates of fibrosis, especially after more than 30 years of follow up. In 
addition, no conclusions can be made with regard to the lack of influence from chronic HBV-
infection on fibrosis progression in this study.  
We did not have direct information on HIV except in the single case where HIV was noted as 
cause of death (Table 1). Among Scandinavian IDUs HIV has played a minor role compared 
with IDUs in other parts of the world including southern Europe [29], and it seems probable 
that the number of HIV positive subjects in the study group was small.  
Another weakness was that the estimation of the fibrosis progression rate was based on only 
one histologic examination, with no biopsies having been taken between the time of infection 
and death. Our conclusions lean on the assumption that fibrosis rates are linear throughout the 
different stages, which is not confirmed [10, 30]. This approximation, however, is of value for 
comparison between this and other studies.  
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There is also a possibility that patients registered as HCV RNA negative could have been 
reinfected after the serum used for our analysis were drawn, and hence may have developed 
chronic HCV infection later. This could explain the development of fibrosis and - in one case 
- cirrhosis among patients registered as HCV RNA negative. Extensive use of alcohol is 
another possible explanation. 
The study was based on PCR analysis of HCV RNA on sera stored at -20 
o
C. This 
temperature might not be sufficient for obtaining correct results, and clearance of HCV is 
somewhat higher than in most studies. Degradation of HCV RNA in some cases cannot be 
excluded. However, HCV clearance in this study is the same as in another Norwegian study 
based on storage at -70 
o
C [31], which might indicate that our HCV RNA results are 
acceptable. 
Out of 220 deaths, 102 were autopsied and included in the study. They had significantly more 
drug related deaths (mainly opioid intoxication) than the 118 with no liver tissue available for 
examination, because death by intoxication is associated with a much higher rate of autopsies 
– mainly forensic - than death caused by disease. It might be hypothesized that liver disease 
could increase the risk of opioid intoxication, resulting in a bias towards patients with 
advanced liver fibrosis in the study group. However, the occurrence of liver disease as a cause 
of death was higher in the comparison group of 118 who were not part in the study (Table 4). 
Instead, this could indicate a higher occurrence of advanced fibrosis in that group compared to 
the study group, and consequently this study may underestimate the true risk of advanced 
fibrosis among IDUs chronically infected by HCV.   
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We may also have underestimated the risk of advanced fibrosis (F3-F4) by our selection of 
the lower score in cases where there was disagreement between the pathologists. Three of 
these were between F2 and F3. 
 
Conclusions 
About 1/3 of IDUs chronically infected by HCV progressed to advanced liver fibrosis within 
three decades after exposure. Without antiviral treatment, a high rate of liver related mortality 
must be expected in this group.  
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Table 1 Cause or manner of death according to HCV RNA 
 
HCV RNA + 
(CHC) 
HCV RNA – 
 Total  
 
N % N % N % 
Drug related 46 75.4 33 80.5 79 77.4 
Suicide 3 4.9 2 4.9 5 4.9 
Homicide 2 3.3 0 0.0 2 2.0 
Accident  3 4.9 2 4.9 5 4.9 
Liver disease 3 4.9 0 0.0 3 2.9 
HIV 1 1.6 0 0.0 1 1.0 
Other disease 3 4.9 4 9.8 7 6.9 
Total 61 100.0 41 100.0 102 100.0 
 
 
 
Table 2 METAVIR fibrosis score according to HCV RNA and duration of HCV-infection 
 Years from HCV 
exposure to 
autopsy 
METAVIR fibrosis score 
Total 
 
F0 F1 F2 F3 F4 
 0-10 0 14 0 0 0 14 
HCV RNA + 10-20 5 14 0 0 2 21 
(CHC) 20-30 2 13 1 2 4 22 
 30-40 0 1 1 1 1 4 
 Total 7 42 2 3 7 61 
 0-10 3 4 0 0 0 7 
HCV RNA - 10-20 1 14 0 0 0 15 
 20-30 1 13 2 0 0 16 
 30-40 0 1 1 0 1 3 
 Total 5 32 3 0 1 41 
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Table 3a Fibrosis, inflammatory activity and steatosis according to HCV RNA 
    
HCVRNA+ 
(CHC) 
HCVRNA- 
 
    N % N % 
 
Fibrosis 
F0-F2 51 83.6 40 97.6 
p=0.026 
F3-F4 10 16.4 1 2.4 
  Total 61 100.0 41 100.0  
        
Inflammatory 
activity 
A0-A1 55 94.8 39 100.0 
p=0.149 
A2-A3 3 5.2 0 0.0 
  Total 56 100.0  39 100.0  
 
       
Steatosis 
S0-S1 45 80.4 36 92.3 
p=0.109 
S2-S3 11 19.6 2 7.7 
 Total 56 100.0 38 100.0 
  
Table 3b Fibrosis according to inflammatory activity and steatosis 
   Inflammatory activity  
  A0-A1 A2-A3  
  N % N %  
Fibrosis 
stage 
F0-F2 85 90,4 1 33,3 
P=0.02 
F3-F4 9 9,6 2 66,7 
Total 94 100,0 3 100,0  
       
  Steatosis  
  S0-S1 S2-S3  
  N % N %  
Fibrosis 
stage 
F0-F2 77 95,1 8 57,1 
P<0.001 
F3-F4 4 4,9 6 42,9 
Total 81 100,0 14 100,0  
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Table 4. Autopsied study group  compared with comparison group without liver tissue 
available for analysis 
  
Study group  
(Liver available) 
N=102 
Comparison group 
(Liver not available) 
N=118 
  
n % n % p-value 
 
Males 76 74.5 85 72.0 0.679 
 
HCV RNA positive 61 59.8 73 61.9 0.755 
 
HBsAg positive 5 6.0 13 13.0 0.109 
       
Cause or manner 
of death 
Drug related 79 77.5 30 25,4 <0.001 
Suicide 5 4.9 15 12.7 0.044 
Accident and homicide 7 6.9 16 13.6 0.105 
Liver disease 3 2.9 9 7.6 0.127 
HIV 1 1.0 11 9.3 0.007 
 
Other disease 7 6.9 37 31.4 <0.001 
       
  
Years SD Years SD 
 Mean time from HCV exposure to death 18.20 8,47 15.84 9,84 
 Mean age at death 38.01 8,52 36.80 10,16 
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Figure 1 Selection of patients for fibrosis study based on liver tissue from autopsies 
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Figure 2 Kaplan-Meier plot on occurrence at autopsy of advanced fibrosis (METAVIR 
stages F3 or F4) according to HCV RNA. Subjects who at autopsy had METAVIR 
stages F0-F2 did not match the end point criteria and thus were censored 
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Figure 3 Stages of liver fibrosis at autopsy in different age groups according to HCV 
RNA 
 
